CALHM1 Antibody | 5593

CALHM1 Antibody | 5593 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Mouse, Rat

Homology: N/A

Immunogen: CALHM1 antibody was raised against a 17 amino acid synthetic peptide near the amino terminus of human CALHM1.
The immunogen is located within amino acids 60 - 110 of CALHM1.

Research Area: Neuroscience

Tested Application: E, WB, IHC-P, IF

Application: CALHM1 antibody can be used for detection of CALHM1 by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in rat samples; Immunohistochemistry in rat samples and Immunofluorescence in rat samples. All other applications and species not yet tested.

Specificiy: N/A

Positive Control 1: Cat. No. 1464 - Rat Liver Tissue Lysate

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: CALHM1 Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: CALHM1 Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: CALHM1 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: CALHM1 Antibody: FAM26C, FAM26C, Calcium homeostasis modulator protein 1, Protein FAM26C

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: CALHM1 Antibody: Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by a massive loss of neurons in several brain regions and by the presence of senile plaques comprised of aggregated amyloid-beta (Abeta) peptides produced by the endoproteolysis of the amyloid precursor protein (APP) . The calcium homeostasis modulator 1 (CALHM1) is a recently identified multipass transmembrane glycoprotein that controls cytosolic Ca2+ concentration and Abeta levels. While some studies suggest CALHM1 is significantly associated with risk of AD, other reports suggest there is no link. CALHM1 has been suggested to modulate the Ca2+-dependent proteolytic process of APP through controlling the level of cytosolic Ca2+.